RxDoctor Payments Data

Keyur Shah, MD

Advanced Heart Failure and Transplant Cardiology · Richmond,, VANPI 1396886362

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.6%.

$62,089in general payments, 2019–2025

Across 182 payments — averaging $341.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • Akcea Therapeutics, Inc.$15K
  • Pfizer$10K
  • Alnylam Pharmaceuticals Inc.$6K
  • Medtronic$5K
  • Abbott$4K
  • plus $8K from 19 others
$572,435in research payments, 2019–2025

Across 72 payments — averaging $7950.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$232K
  • Ionis Pharmaceuticals, Inc.$91K
  • Amgen$67K
  • Ortho-clinical Diagnostics, Inc.$60K
  • Eidos Therapeutics, Inc.$56K
  • Pfizer$32K
  • plus $34K from 3 others

What the payments were for

  • Consulting fees$19,47331%
  • Speaking & faculty fees$28,81646%
  • Travel & lodging$3,2895%
  • Food & beverage$10,47917%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,089 in reported general payments places this provider in the 85th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.

See all advanced heart failure and transplant cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$73,675
Medicare patients
263
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis204$4,956,358
VyndaqelTafamidis Meglumine59$1,183,153
EntrestoSacubitril/Valsartan179$207,207
FarxigaDapagliflozin Propanediol156$179,335
JardianceEmpagliflozin108$107,800
EliquisApixaban98$91,268
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres12$59,252
XareltoRivaroxaban15$12,781
Torsemide108$3,327
Eplerenone44$3,324
Metoprolol Succinate122$2,570
Potassium Chloride34$1,783
Bumetanide23$1,168
Warfarin Sodium74$1,089
Amiodarone Hcl65$1,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$9,989$6,230,779361 claims
NovartisEntresto, Sandostatin Lar Depot$573$266,459191 claims
AstraZenecaFarxiga$14,647$179,335156 claims
Boehringer IngelheimJardiance$29$107,800108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.

Other advanced heart failure and transplant cardiology in Richmond,

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →